Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
Current Issues in Molecular Biology · 12.11.2023 · 45 (11) · 9019-9038
DOI: 10.3390/cimb45110566 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 12.11.2023. Verfasst von Hong Yun Ma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Columbia University Irving Medica Center, 622 W 168th St., New York, NY 10032, USA. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte. CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intracellular signaling domain responsible for T cell activation, and a hinge that joins these two domains. Continuous improvement has been made in CARs, now in their fifth generation, particularly in the intracellular signaling domain responsible for T cell activation. CAR T cell therapy has revolutionized the treatment of hematologic malignancies. Nonetheless, the use of CAR T cell therapy for solid tumors has not attained comparable levels of success. Here we review the challenges in achieving effective CAR T cell therapy in solid tumors, and emerging CAR T cells that have shown great promise for non-small cell lung cancer (NSCLC). A growing number of clinical trials have been conducted to study the effect of CAR T cell therapy on NSCLC, targeting different types of surface antigens. They include epidermal growth factor receptor (EGFR), mesothelin (MSLN), prostate stem cell antigen (PSCA), and mucin 1 (MUC1). Potential new targets such as erythropoietin-producing hepatocellular carcinoma A2 (EphA2), tissue factor (TF), and protein tyrosine kinase 7 (PTK7) are currently under investigation in clinical trials. The challenges in developing CAR T for NSCLC therapy and other approaches for enhancing CAR T efficacy are discussed. Finally, we provide our perspective on imaging CAR T cell action by reviewing the two main radionuclide-based CAR T cell imaging techniques, the direct labeling of CAR T cells or indirect labeling via a reporter gene.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Columbia University Irving Medica Center, 622 W 168th St., New York, NY 10032, USA.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
- RefleXion Medical Inc., Hayward, CA 94545, USA.
ORCID-Profile: Dorine De Jong, Mahdie Hosseini
Förderung
- NCI NIH HHS
Zitieren
APA
Ma, H. Y., Das, J., Prendergast, C., De Jong, D., Braumuller, B., Paily, J., Huang, S., Liou, C., Giarratana, A., Hosseini, M., Yeh, R., & Capaccione, K. M. (2023). Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer. Current Issues in Molecular Biology, 45(11), 9019-9038. https://doi.org/10.3390/cimb45110566
Vancouver
Ma HY, Das J, Prendergast C, De Jong D, Braumuller B, Paily J, et al. Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer. Current Issues in Molecular Biology. 2023;45(11):9019-9038. doi:10.3390/cimb45110566
BibTeX
@article{Ma2023,
author = {Ma, Hong Yun and Das, Jeeban and Prendergast, Conor and De Jong, Dorine and Braumuller, Brian and Paily, Jacienta and Huang, Sophia and Liou, Connie and Giarratana, Anna and Hosseini, Mahdie and Yeh, Randy and Capaccione, Kathleen M},
title = {Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer},
journal = {Current Issues in Molecular Biology},
year = {2023},
volume = {45},
number = {11},
pages = {9019--9038},
doi = {10.3390/cimb45110566}
}
EUVIMED